 Life Science Investor Mandates
(Dec. 1
- Dec. 7)
|
|
|
Invests in Clinical Stage Biopharma, Devices and Digital Health
|
Looking Early for Information-Enabled Devices, Delivery Devices and Point of Care Diagnostics
|
Raises New Fund for Biotech and Medical Device Opportunities
|
Invests in Therapeutic Platforms, Diagnostics, Digital Health and Home Care
|
Click to see investors that are a fit for your product and stage of development
|
Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you
|
Click here if you want to receive free, targeted early stage dealflow for your life science investment firm
|
|
|
A year ago, we were overwhelmed by demand for RESI San Francisco, and to our surprise we had to close registrations two weeks early as we'd reached capacity. We have increased space over last year - however, RESI @ JPM at the Marines' Memorial Club is fast approaching sellout at 75% of capacity, and is expecting to host over 2000 scheduled and ad hoc meetings in one high energy day. This is a record-setting pace for Life Science Nation and the RESI Conference. We expect to close registration well before January 10th, perhaps even before New Year's Day!
The growth of RESI into a must-go-to event during JPMorgan week, is owed to our near-equal ratio of investors to fundraising executives paired with our unique partnering platform rich with investor data - an amazing feat that is only possible due to the strength of LSN's investor network...
|
 |
With RESI partnering having launched this week we wanted to provide a quick video tutorial on how to use the platform most effectively. The video below shows a step by step demonstration of the platform and how it can be used to parse through and identify the hundreds of companies and investors that will be in attendance on January 10th. By using this platform, you can identity relevant groups and book up to 16 meetings throughout the day...
|
 |
The various panels that run throughout the day at every RESI conference serves to educate entrepreneurs on how various investors (VCs, corporates, angels, family offices, etc.) are looking at innovation in their specific sector and tactical guidance for how to approach and interact with them, including the nuances of commercializing these technologies and current happenings in their respective market. Medtech, especially in recent years, has taken a backseat to biopharma with lower valuations and fewer exit partners, however many early-stage investors and entrepreneurs alike, still believe there is value to be unlocked.
During RESI@JPM, a group of seasoned medical device investors will explore the state of the early-stage medtech space, discuss personal successes and failures in funding novel medical technologies and share with the entrepreneurs in the audience do's and don'ts of fundraising in this challenging sector.
Medical Device investor panelists will include the following:
- Sam Ifergan, President & CEO, iGan Partners (moderator)
- Ena Prosser, Partner, Fountain Healthcare Partners
- Gerry Brunk, Managing Director, Lumira Capital
- Brent Ahrens, General Partner, Canaan Partners
- Louis Cannon, Founder & Senior Managing Director, BioStar Ventures
|
 |
 |
 |
|
|